Knight Therapeutics (OTCMKTS:KHTRF) Shares Up 2.7%

Knight Therapeutics Inc. (OTCMKTS:KHTRF) shot up 2.7% during mid-day trading on Thursday . The stock traded as high as $4.21 and last traded at $4.21. 10,900 shares were traded during mid-day trading, an increase of 67% from the average session volume of 6,535 shares. The stock had previously closed at $4.10.

Knight Therapeutics Stock Up 2.7 %

The firm’s 50 day moving average price is $4.24 and its 200-day moving average price is $4.12.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.